Mirtazapin Alternova (Mirtazapine)

Mirtazapine works by blocking presynaptic α2‑adrenergic receptors, increasing the release of norepinephrine and serotonin. It also antagonizes 5‑HT2, 5‑HT3 and histamine H1 receptors, enhancing mood and producing a sedative effect that can improve sleep.

The appropriate dose of Mirtazapin Alternova is determined by the prescribing clinician based on the individual’s clinical condition, response, and tolerability. Dosage adjustments are made according to professional guidelines and patient needs.

Safety data for mirtazapine in pregnancy and lactation are limited, and the product’s pregnancy category is unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mirtazapin Alternova belongs to the NaSSA class, differing from SSRIs and SNRIs by its dual antagonism of α2‑adrenergic and specific serotonin receptors. This mechanism often results in pronounced sedative and appetite‑stimulating effects, which can be advantageous for patients with insomnia or weight loss, but may be less suitable for those concerned about weight gain.

Store Mirtazapin Alternova at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mirtazapin Alternova is taken orally, usually once daily in the evening due to its sedative properties. The tablet should be swallowed whole with water and not chewed or crushed unless otherwise directed by a healthcare professional.

Serious risks include the potential for agranulocytosis, severe neutropenia, serotonin syndrome when combined with other serotonergic drugs, and the emergence or worsening of suicidal thoughts, particularly during the initial treatment period. Prompt medical attention is required if any of these events occur.

Mirtazapin Alternova should be avoided in patients with known hypersensitivity to mirtazapine or any excipients, those currently taking MAO inhibitors, or individuals with severe hepatic impairment without appropriate dose adjustment. Clinicians must also exercise caution in patients with a history of bipolar disorder, as antidepressants can precipitate mood switching.